tarcocimab tedromer
tarcocimab tedromerbiologicanti-VEGF antibody biopolymer conjugate
Wet AMD
Phase 3
1 program·1 trial·View drug →
DashboardBuy9,997$14.67+$146.6KOption ex.7,308$11.62$84.9KOption ex.352,820$11.37$4.0MBuy74,447$11.02+$820.2KBuy20,917$13.80+$288.7KOption ex.15,223$15.04$229.0KSell34,865$16.04−$559.3K Internal MedicineCo-Investigator$350.4K7EndocrinologyCo-Investigator$298.7K3EndocrinologyResearch Grant$277.4K5Diabetes & MetabolismCo-Investigator$265.5K3Diabetes & MetabolismResearch Grant$253.3K6EndocrinologyCo-Investigator$226.9K5Internal MedicineCo-Investigator$214.7K7Diabetes & MetabolismEquity / Ownership$198.1K2Diabetes & MetabolismEquity / Ownership$188.6K3Diabetes & MetabolismEquity / Ownership$176.3K4
KODNASDAQ
Kodiak Sciences
Kodiak Sciences Inc. · Palo Alto, CA · founded 2009
Kodiak Sciences, based in Palo Alto, California, develops therapies for retinal disease using its antibody-biopolymer-conjugate platform — designed to extend dosing intervals so patients receive fewer eye injections. Lead candidate tarcocimab is in pivotal trials for wet age-related macular degeneration and diabetic macular edema, conditions currently treated with monthly or bi-monthly intravitreal injections.
- Lead asset
- tarcocimab tedromer · Ph3 · Wet AMD
- biologic · anti-VEGF antibody biopolymer conjugate
- Pipeline
- 1 drug · 1 program
- 1 Other
- Modalities
- biologic×1
FocusOther
$5.60-5.08%1Y
KOD · daily close · illustrative · 1 catalyst marked
P3 readout+27%
1Y high$6.041Y low$4.32range$1.72(40%)past catalysts
Peers in this space
Pipeline & catalysts
Pipeline & catalysts
Pipeline by phase1programs
- Preclin0
- Ph10
- Ph20
- Ph31
- Filed0
- Approved0
Past catalyst impact
DateKindEventOutcome+1W+1M+6M
May 30, 2025Readouttarcocimab tedromer — Phase 2b Topline Met Primary EndpointPositive+27.3%+41.8%+36.2%
Mar 31, 2025Readouttarcocimab tedromer — Phase 2b Topline Met Primary EndpointNegative-29.4%-27.5%-15.0%
Jan 30, 2025Enroll.tarcocimab tedromer — Pivotal Enrollment CompleteNegative-5.8%-5.9%-6.1%
Oct 8, 2023Conf.tarcocimab tedromer — ASH Late-Breaker — Updated SurvivalPositive+7.3%+7.8%+3.0%
% change vs ticker close on the announcement date · backtest illustrative
Smart money
Insider activity
Insider activity · last 90 days
Form 4 trail · 7 transactions · 7 insiders
Net flow
+$696.2K
Buys
$1.3M
3 txns
Sells
$559.3K
1 txns
Largest
+$820.2K
CEO buy
Net flow per quarter · last 8Q
12 txns · sum +$614K
24Q325Q125Q326Q126Q2
buys · $1.72Msells · $1.11M
Insider · roleActionSharesPriceValueDate
L. Kowalski
CSO
Apr 22, 2026
R. Patel
Director
Apr 21, 2026
P. Voss
10% Owner
Mar 25, 2026
A. Reyes
CEO
Mar 15, 2026
K. Voss
Director
Mar 7, 2026
L. Chen
COO
Feb 22, 2026
C. Chen
CFO
Jan 29, 2026
Congressional trading
Congressional trading · STOCK Act · last 365d
4 trades · 4 members
Est. net flow
+$141K
midpoint · brackets only
Buys
3
Sells
1
Party mix
2 D2 R
Member · chamberActionBracket~ midpointOwnerDate · disclosure
R
Buy$100K–$250K~$175KspouseSen. D. Greenwood
Senate · TX
Feb 11, 2026
filed +32d
R
Sell$50K–$100K~$75KspouseRep. G. Ostrom
House · OH
Sep 27, 2025
filed +41d
D
Buy$15K–$50K~$33KjointSen. A. Reyes
Senate · CA
Aug 28, 2025
filed +22d
D
Buy$1K–$15K~$8KselfRep. K. Linville
House · WA
Jun 5, 2025
filed +40d
Source: Senate eFD & House Clerk PTR feeds · members must disclose within 45 days · midpoints reflect bracket midpoint, not actual transaction value
Top ETF holders
ETF holders · NAV disclosures
3 ETFs hold the position
Held by ETFs
$11.5M
aggregate position
Of market cap
3.58%
aggregate ETF share
Top holder
SBIO5.11%
ALPS Medical Breakthroughs ETF
TickerETF · familyThemeNAV% of NAVPosition
SBIOSmall-cap biotech$110.0M5.11%$5.6M
ALPS Medical Breakthroughs ETF
First Trust
IBBBroad biotech$8.40B0.04%$3.4M
iShares Biotechnology ETF
iShares
BBCSmall-cap biotech$60.0M4.12%$2.5M
Virtus LifeSci Biotech Clinical Trials
WisdomTree
Source: ETF NAV disclosures + quarterly 13F filings · narrow-theme ETFs disclose holdings daily; broad ETFs quarterly · % of NAV is the position weight inside the fund
KOL network
KOL network · CMS OpenPayments
15 physicians paid · 59 disclosed records
Total 2025+2024
$2.82M
YoY
+29%
Co-Investigator$975.3KEquity / Ownership$860.6KResearch Grant$625.9KSpeaking$182.3KConsulting$150.0KTravel & Lodging$25.7KFood & Beverage$2.3K
Physician · affiliationSpecialtyTop categoryTotalRecords
Dr. Sofia Park
Duke University
Dr. Sofia Davies
UCSF
Dr. James Tanaka
UCSF
Dr. Yuki Goldstein
Mayo Clinic
Dr. Rebecca Iyer
University of Washington
Dr. Liam Chen
Penn Medicine
Dr. Charles Park
Duke University
Dr. Maya Greene
Stanford Medicine
Dr. Yuki Romano
Penn Medicine
Dr. Ahmed Mendoza
Stanford Medicine
Source: CMS OpenPayments · quarterly drops · physicians identified by NPI · aggregated across all programs
Government & IP
Federal lobbying
Federal lobbying · LDA · last 8 quarters
$273K disclosed · 2 firms engaged
YoY change
+24%
last 4Q vs prior 4Q
24Q3Q425Q1Q2Q3Q426Q1Q2
Top lobbying firms · last 8Q
Tiber Creek Group$187K
7 quarters active
Invariant$86K
4 quarters active
Top issues lobbied
- Prescription Drug User Fee programs$91K
- Rare Pediatric Disease Priority Review Voucher$62K
- Accelerated approval pathway reforms$62K
- Medicare coverage for CAR-T$29K
- Medicare Part B coverage for gene therapies$29K
Source: Senate LDA database (lda.senate.gov) · quarterly registrant filings · spend is the company-wide total disclosed
Government contracts
Federal contracts · USAspending.gov
2 awards · 2 agencies
Total awarded
$23.1M
across all programs
Active
$20.8M
option periods incl.
Top agency
NIH / NHLBI$20.8M
largest active: Cardiovascular Outcomes Trial Co-Funding
AgencyTitle · type · award IDStatusValueAwarded → ends
NIH / NHLBIactive$20.8MDec 2024→ Aug 2026
Cardiovascular Outcomes Trial Co-Funding
Cooperative Agreement · NIH-66013687
VAcompleted$2.3MJun 2023→ Nov 2024
Veterans Health Administration — Specialty Drug Supply
Contract · VA-67137409
Source: USAspending.gov · SAM.gov · every federal contract / grant / cooperative agreement is public · values are obligated awards (may include option periods)
U.S. Patents
U.S. Patents · USPTO
3 granted · 3 pending
Total in portfolio
6
Granted in last 12mo
0
Expiring < 2yr
0
Nearest expiry
Apr 2032
Patent #Title · inventor · drugTypeStatus · filedExpiry
US 2024/3801740 A1Method of Use
Methods of stratifying patients for treatment with tarcocimab tedromer
B. Park + 2 · tarcocimab tedromer
pendingfiled Apr 2024
in prosecution
US 2024/3564998 A1Formulation
Subcutaneous injectable formulations of tarcocimab tedromer
P. Andersson + 4 · tarcocimab tedromer
pendingfiled Apr 2024
in prosecution
11,916,102Formulation
Subcutaneous injectable formulations of tarcocimab tedromer
R. Voss + 1 · tarcocimab tedromer
grantedfiled Apr 2021
exp. Apr 2041
15.0y left
US 2018/7500487 A1Method of Use
Methods of stratifying patients for treatment with tarcocimab tedromer
D. Romano + 3 · tarcocimab tedromer
pendingfiled Apr 2018
in prosecution
10,979,930Composition of Matter
Therapeutic peptide compositions for tarcocimab tedromer
D. Kim + 3 · tarcocimab tedromer
grantedfiled Apr 2014
exp. Apr 2034
8.0y left
11,378,246Composition of Matter
Bispecific antibody compositions targeting tarcocimab tedromer
C. Schwartz + 2 · tarcocimab tedromer
grantedfiled Apr 2012
exp. Apr 2032
6.0y left
Source: USPTO PEDS & Patent Public Search · composition-of-matter is the headline asset · expiration = 20 years from filing
News
News
News · last 90 days
5 items from 4 categories
regulatory2corporate1partnership1clinical1
4d ago
KOD expands manufacturing capacity at lead facility
Business Wire·corporate
4d ago
FDA accepts KOD's NDA for tarcocimab tedromer; PDUFA date set
PR Newswire·regulatory
2mo ago
FDA grants Breakthrough Therapy Designation to KOD's tarcocimab tedromer
FierceBiotech·regulatory
2mo ago
KOD enters licensing agreement with major pharma for tarcocimab tedromer
Business Wire·partnership
2mo ago
KOD reports topline results from Phase 2 trial of tarcocimab tedromer
Endpoints News$·clinical
Sources: PR wires + biotech-trade publications + company IR · paywalled outlets ($) link to publisher · we never paraphrase the headline
Financials
Financials
Trading
Previous close
$5.60
Open
$5.57
Day Δ
+0.03
+0.54%
Day range
$5.54 – $5.63
52W range
$4.32 – $6.04
Avg daily volume
766K
Valuation & ownership
Enterprise value
$213M
Shares out
57.14M
Float
48.57M
Insider %
10.92%
Institutional %
60.92%
Beta
1.42
vs SPY · 52w
Balance sheet & burn
Cash + invest
$208M
Total debt
$192M
Debt / equity
1.92
Cash burn / Q
$36M
R&D spend TTM
$133M
64% of cash
ATM available
$54M
dilution risk
Earnings
EPS latest
$-0.77
EPS Δ vs prior
+0.12
EPS estimate
$-0.75
next quarter
EPS prior
$-0.89
Next earnings
Jun 14, 2026
Rev guidance
$5M